If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
173
results.
Updated on
19/04/2025 [07:15:00]
Absstract of: US2025122153A1
Provided herein, inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III)and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.
Absstract of: US2025121054A1
Disclosed herein are nucleic acid molecules encoding a SARS-CoV-2 spike antigen. SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection in a subject.
Absstract of: US2025123269A1
A robust human cell culture model permissive to both SARS-COV-2 variants and MERS-COV is critical for assessment and validation of antivirals. Human alveolar A549 cells are regarded as a valuable model for respiratory virus infection. SARS-COV-2 uses the angiotensin converting enzyme 2 (ACE2) receptor for viral entry and the transmembrane serine protease 2 (TMPRSS2) to prime the SARS-COV-2 spike protein. By contrast, MERS-COV utilizes the dipeptidyl peptidase 4 receptor (DPP4) to enter the target cells. Three of which are negligibly expressed in A549. Disclosed herein is a generation of a robust human cell model that carries DPP4, ACE2, and TMPRSS2 receptor expressions. By transducing Dpp4 into A549-ACE2plusC3 cells (ACE2+/TMPRSS2+), the resulting cells expressing DPP4, ACE2 and TMPRSS2 (“ACE2plusC3D4”) are highly susceptible to MERS-COV and SARS-CoV-2 omicron infection. This ACE2plusC3D4 cell model can be applied for evaluation of antiviral drugs and potentially developed for high-throughput screening.
Absstract of: US2025122243A1
The present invention is directed to a composition, mammalian cell and vector, and a method for the production of, and method of treatment with, a recombinant protein vaccine in a mammalian cell line. The methods and compositions are particularly useful for generating the stable expression of a recombinant protein vaccine of interest. The invention is particularly useful for the production of vaccines to aid in protection against viral pathogens for vertebrates, in particular mammalians, especially humans. The mammalian cell for producing a protein of interest comprises: a plasmid encoded with a nucleotide sequence encoding one or more epitopes or subunits of the SARS-CoV-2 that are embedded in the nucleotide sequence encoding a detoxified recombinant tetanus toxin (DrTeNT).
Absstract of: US2025123274A1
Methods for obtaining a population of differentiated alveolar cells, differentiated alveolar cells in the form of alveolar organoids generated by the methods and uses for the differentiated alveolar organoids are provided. The methods include digesting long-term expanding lung organoids (LO) into single cells (i.e., dissociated cells), and suspension culturing the dissociated cells in distal differentiation (DD) cell culture media in a non-adherent plate for an effective amount of time. Alveolar organoids includes a population of AT1 and AT2 cells and in suspension culture exhibit an apical-out polarity and include abundant cytoplasmic lamellar bodies and microvilli. The alveolar organoids can be utilized alone or in combination with 2D and 3D AWO, rebuilt the human respiratory epithelium in culture plates for studying biology and pathology of human respiratory system, including, but not limited to, the study of COVID-19 respiratory diseases.
Absstract of: US2025121052A1
Disclosed herein are vaccine compositions that include SARS-CoV-2 MHC epitope-encoding cassettes and/or full-length SARS-CoV-2 proteins. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.
Absstract of: US2025121053A1
The invention relates to immunogenic compositions and their use as a vaccine for the prevention of coronavirus disease in a human subject. More specifically, the invention relates to methods of use of an immunogenic composition in the prevention of coronavirus disease in a human subject in need thereof, said immunogenic composition comprising: a fusion protein comprising (i) a SARS-Cov2 nucleocapsid N antigen and, (ii) a carrier protein comprising a self-assembling polypeptide derived from C4bp oligomerization domain and a positively charged tail.
Absstract of: GB2634646A
A bacteriophage T4-based, multivalent/multicomponent, needle and adjuvant-free, mucosal vaccine by engineering spike trimers on capsid exterior and nucleocapsid protein in the interior is disclosed herein. Intranasal administration of this T4-COVID vaccine induces higher virus neutralization antibody titers against multiple variants, balanced Th1/Th2 antibody and cytokine responses, stronger CD4+ and CD8+ T cell immunity, and higher secretory IgA titers in sera and bronchoalveolar lavage with no effect on the gut microbiota, compared to vaccination of mice intramuscularly. The vaccine is stable at ambient temperature, induce apparent sterilizing immunity, and provide complete protection against original SARS-CoV-2 strain and its Delta variant with minimal lung histopathology. This mucosal vaccine is an excellent candidate for boosting immunity of immunized and/or as a second-generation vaccine for the unimmunized population. This needle-free platform could be used to develop effective vaccines against many other respiratory infectious pathogens including Flu and any future emerging epidemic and pandemic pathogens.
Absstract of: AU2023283718A1
The present disclosure relates to methods for treating viral infections in a patient that is not pregnant. Also provided are combination treatments for viral infections in a human in need thereof.
Absstract of: WO2025073771A1
The present invention inter alia relates to an use of an isolated polypeptide or an antigenic fragment thereof, comprising a polypeptide region having at least 60% sequence identity with any one of the polypeptide sequences selected from the group consisting of SEQ ID No.: 1-11, 16-20 and 23-28; wherein the isolated polypeptide is having a length of no more than 200 contiguous amino acids for diagnosing Long COVID or Post-Vac-Syndrome, or for predicting a risk of developing Long COVID or Post-Vac-Syndrome. The present invention also relates to the isolated polypeptide or antigenic fragment thereof for use in preventing, treating or ameliorating Long COVID or Post-Vac-Syndrome., as well as to a method of detecting a presence of antibodies against SARS-CoV-2 in a subject, comprising the step of contacting a sample of said subject with at least one of the polypeptide or antigenic fragment thereof.
Absstract of: US2025116673A1
Disclosed are methods for identifying or determining whether a subject exhibits a CD4+ memory T cell response to SARS-CoV-2 infection or vaccination, assessing the efficacy of a SARS-CoV-2 vaccine, and developing personalized SARS-CoV-2 treatment plans by detecting the presence and/or quantity of a particular T cell receptor a chain that recognizes a specific Spike protein epitope.
Absstract of: US2025116668A1
Diagnostic assay devices for detecting the presence of an analyte in a sample solution may comprise a microreactor configured to form a sample solution containing the analyte, flow the sample solution therethrough in a first direction to form an analyte-capture molecule complex, and transfer the sample solution to an absorbent strip pad configured to flow therethrough, in a second direction crossing the first direction, the sample solution including the analyte-capture molecule complex and indicate a presence of the analyte-capture molecule complex. In some embodiments the devices are configured to process a bioaerosol sample. In some embodiments the diagnostic assay devices may be multiplexed and may be used for detecting the presence of two or more analytes in a sample solution. The diagnostic devices may be used, for example, to identify the presence of one or more of SARS-Cov2, RSV, influenza A, influenza B or other pathogens in samples from patients.
Absstract of: US2025114445A1
The present disclosure relates to extracellular vesicles comprising one or more antigens from a coronavirus (e.g., SARS-CoV-1 or SARS-CoV-2) and optionally an adjuvant. Also provided herein are methods for producing the EVs and methods for using the EVs to treat and/or prevent diseases or disorders, e.g., infectious diseases.
Absstract of: US2025114418A1
The present invention relates to the use of extracts from Boswellia species and pharmaceutical compositions comprising Boswellia extracts in the treatment of SARS-CoV-2 infection and related medical conditions.
Absstract of: US2025114425A1
A composition for the treatment of or prevention of COVID-19 or long COVID may be a mixture of: water; green tea; lemon juice; red onions; and garlic. One embodiment of the composition may be made by including a plurality of bags of green tea, sliced lemons, lemon juice, cut red onion pieces, and a plurality of cut garlic pieces in water, boiling the composition for about 30 minutes, and then straining the composition. A piece of smashed ginger may be added to the composition prior to boiling. A cup of the composition may be drunk three or more times a day to treat a person having COVID-19, or a cup or more of the composition may be drunk daily to prevent COVID-19.
Absstract of: AU2023353878A1
Described herein is evolution strategy that leverages highly efficient tRNA charging chemistry for cell-free ribosomal translation of proteins, including fluorogenic sensors. The fluorogenic sensors provided are capable of detecting targets, including antigens such as SARS-CoV-2 variants (
Absstract of: WO2025076406A1
The synthesis and characterization of a series of derivatives and analogs based on the 9-aminoacridine scaffold shared by antimalarial drugs quinacrine and pyronaridine are described. Also described is the structure-activity relationship of these compounds against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease of 2019 (COVID-19). Several compounds displayed potent in vitro activity, with 50% inhibitory concentrations below 1 micromolar.
Absstract of: WO2025075129A1
Provided are coronavirus spike protein variants for use as antigens for vaccines for coronavirus infections. The present invention provides coronavirus spike protein variants comprising (a) a receptor binding domain (RBD) formed from the amino acid sequence set forth in SEQ ID NO: 1, (b) an RBD formed from an amino acid sequence in which one to several amino acids have been substituted, deleted, inserted, or added in the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to RBD formed from the amino acid sequence set forth in SEQ ID NO: 1, or (c) an RBD formed from an amino acid sequence having at least 90% sequence identity with the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to RBD formed from the amino acid sequence set forth in SEQ ID NO: 1.
Absstract of: US2025114044A1
Embodiments of the present disclosure generally relate to methods for analyzing outcomes of illnesses, such as COVID-19, on living organisms. More particularly, embodiments of the present disclosure relate to methods for identifying risk of illness based on genetic markers and other available data, predicting results of mass exposure to an Illness based on a populations genomes and other available data, and providing indicators and methods of visualization for probability of illness in any living organism.
Absstract of: US2025114389A1
Compounds, compositions and methods for preventing, treating or curing a coronavirus infection in human subjects or other animal hosts. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1, OC43, and SARS-CoV-2. In another embodiment, the methods are used to treat a patient infected with a Flavivirus, Picornavus, Togavirus, or Bunyavirus.
Absstract of: US2025114394A1
The composition inhibits severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) via competitive binding to SARS-COV-2 spike protein. The composition includes a plurality of sulfated glycosaminoglycans which bind to SARS-COV-2 spike protein, preventing binding to and uptake by host cells. The sulfated glycosaminoglycans, including N-, 2-O, 3-O, or 6-O sulfate groups, or combinations thereof, include heparins and fucoidans, such as those isolated from brown seaweed. The compositions show antiviral activity, with EC50 as low as 0.08 μM, and low cytotoxicity, making it promising for clinical use. While established SARS-COV-2 treatments such as remdesivir need to be administered intravenously, the compositions discussed herein are advantageously capable to being delivered as a nasal spray, metered dose inhaler, oral delivery, etc.
Absstract of: US2024376178A1
The invention relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.
Absstract of: US2023393124A1
In certain aspects, disclosed are methods and systems for detecting SARS-CoV-2 analytes in dried samples, as for example, dried blood spots. For example, disclosed are methods for measuring an antibody to SARS-CoV-2 in a dried sample that include the steps of: (a) obtaining a dried sample from a subject; (b) extracting the SARS-COV-2 antibody from the dried sample; and (c) detecting the SARS-COV-2 antibody extracted from the dried sample. In certain embodiments, the method is semi-quantitative. The method may, in certain embodiments, further comprise obtaining measurements from an individual over a period of time to follow the titer of SARS-CoV-2 antibody in the individual. For example, the titer may be followed in the individual for at least 19 weeks or longer.
Absstract of: AU2023276011A1
The present invention relates to the construction of Adenovirus-based vectors und to their use for inducing a broad, robust and durable cellular and humoral immune response in a subject.
Nº publicación: EP4531906A1 09/04/2025
Applicant:
US HEALTH [US]
The United States of America, as represented by The Secretary, Department of Health and Human Services
Absstract of: WO2023235863A1
Engineered SARS-CoV-2 variants having a combination of attenuating modifications, and their use as live-attenuated SARS-CoV-2 vaccines, are described. The recombinant genome of the live-attenuated SARS-CoV-2 encodes a modified spike (S) protein with a deletion of the polybasic site (DPRRA); encodes a modified non-structural protein 1 (Nsp1) with K164A and H165A substitutions; and includes a mutation that prevents expression of open reading frames (ORFs) 6, 7a, 7b and 8. The disclosed live-attenuated SARS-CoV-2 retain the capacity to infect and replicate in mammalian cells. Immunogenic compositions that include a live-attenuated SARS-CoV-2 and methods of eliciting an immune response against SARS-CoV-2 in a subject are also described. Further disclosed are a collection of reverse genetics plasmids that include the complement of the recombinant genome of the live-attenuated SARS-CoV-2 and methods of producing a live-attenuated SARS-CoV-2 using the reverse genetics plasmids.
BOPI
Electronic site
